- MHY 1485
-
- $0.00 / 100mg
-
2022-04-01
- CAS:326914-06-1
- Min. Order: 100mg
- Purity: 99%
- Supply Ability: 10 g
- MHY1485
-
- $0.00 / 100mg
-
2022-03-24
- CAS:326914-06-1
- Min. Order: 50mg
- Purity: 98%
- Supply Ability: 100g
|
| | MHY1485 Basic information |
| Product Name: | MHY1485 | | Synonyms: | MHY1485;4,6-dimorpholino-N-(4-nitrophenyl)-1,3,5-triazin-2-amine;4,6-Di-4-morpholinyl-N-(4-nitrophenyl)-1,3,5-triazin-2-amine;MHY-1485;MHY 1485;1,3,5-Triazin-2-amine, 4,6-di-4-morpholinyl-N-(4-nitrophenyl)-;4,6-Bis(morpholin-4-yl)-N-(4-nitrophenyl)-1,3,5-triazin-2-amine;MHY1485 USP/EP/BP | | CAS: | 326914-06-1 | | MF: | C17H21N7O4 | | MW: | 387.39 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 326914-06-1.mol |  |
| | MHY1485 Chemical Properties |
| Melting point | 256-259 °C | | Boiling point | 643.3±65.0 °C(Predicted) | | density | 1.415±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO: soluble2mg/mL, clear (warmed) | | pka | 6.19±0.10(Predicted) | | form | powder | | color | white to beige | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or DMF may be stored at -20°C for up to 3 months. |
| WGK Germany | 3 | | HS Code | 2934.99.3900 |
| | MHY1485 Usage And Synthesis |
| Description | MHY1485 is a cell-permeable activator of mTOR that has been shown to increase levels of cellular mTOR Ser2448 and downstream substrate 4E-BP Thr37/46 phosphorylation in rat liver Ac2F cells. It can induce cellular LC3-II accumulation in Ac2F cells and has been shown to inhibit autophagy by suppressing the fusion between autophagosomes and lysosomes. | | Uses | MHY1485 has been used:
- to study the effect of mammalian target of rapamycin mTOR signalling on in vitro O-GlcNAcylation
- to inhibit autophagy
- as a mTOR agonist to demonstrate that the O-linked N-acetylglucosamine transferase- RNA helicase p68 (OGT-DDX5) axis regulates colorectal cancer cell proliferation and metastasis
| | Biochem/physiol Actions | MHY1485 is mTOR activator that potently inhibits autophagy by suppression of fusion between autophagosomes and lysosomes. | | References | 1) Choy et al. (2012), Inhibitory effect of mTOR activator MHY1485 on autophagy: suppression of lysosomal fusion; PLoS One, 7(8) e43418
2) Cheng et al. (2015), Promotion of ovarian follicle growth following mTOR activation: synergistic effects of AKT stimulators; PLoS One, 10(2) e0117769
3) Zhao et al. (2016), MHY1485 activates mTOR and protects osteoblasts from dexamethasone; Biochem. Biophys. Res. Commun., 481 212
4) Yang et al. (2017), MHY1485 ameliorates UV-induced skin cell damages via activating mTOR-Nrf2 signaling; Oncotarget, 8 12775
5) Li and Siragy (2015), (Pro)renin receptor regulates autophagy and apoptosis in podocytes exposed to high glucose; J. Physiol. Endocrinol. Metab., 309 E302 |
| | MHY1485 Preparation Products And Raw materials |
|